Scaled Average Bioequivalence [Regulatives / Guidelines]

posted by graveendranath – 2010-01-06 08:36 (5642 d 21:20 ago) – Posting: # 4563
Views: 6,378

Dear Helmut,

We want to conduct a study with partial replicated design (Reference twice) for Europe regulatory. My doubt is

1. Does the Europe Regulatory accepts the Scaled Average Bioequivalence method for highly variable drugs?
2. If we can show that the Intra cv for reference product is > 30% then can we use wider limits (75-133)?

Thank You

Rgds
Raveendranath

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
52 visitors (0 registered, 52 guests [including 6 identified bots]).
Forum time: 06:57 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5